This review looks at demystifying the intricate ways in which sex-specific biology contribute to differences in pathogenesis, as well as discussing future research directions. From: Christa Lam, et al., Bladder Cancer, Vol.8, Iss.3, pp. 241–254, 2022

This review looks at the rationale investigate the BCG vaccination against COVID-19. Visual illustrates how BCG-induced trained immunity could prevent COVID-19 infections. From: Noval Rivas, et al., Bladder Cancer, Vol.7, Iss.2, pp. 121–131, 2021

Bladder Cancer guest blog launched Our first contributor is Bladder Cancer board member Jennifer M. Taylor, MD, MPH (Baylor College of Medicine) who shares a post that covers an exceptional legacy in urology – the first mother and daughter to both become urologists. Click visual to view!

Bladder Cancer reached the 2K milestone on Twitter in May 2021. Thanks to all our followers in the research community and to our social media editors Bishoy Faltas & Kyrillus Shohdy for spreading word about the new content published in the journal. Follow us at: @BladderCaJrnl

This study identifies findings from important clinical and mechanistic studies on the urinary microbiome and future opportunities to impact prevention and treatment of bladder cancer. From: Andolfi, et al., Bladder Cancer, Vol.6, Iss.3, pp. 225–235, 2020

This study analyzes field cancerization in bladder cancer patients using a non-tumor guided approach. The visual illustrates the study design. From: Strandgaard, et al., Bladder Cancer, Vol.6, Iss.3, pp. 253–264, 2020

Schematic showing the distribution of recurrent non-coding mutations across expression subtypes from the article looking at non-coding mutations in urothelial bladder cancer. From: Jeeta, et al., Bladder Cancer, Vol.5, Iss.4, pp. 263–272, 2019

Schematic showing conceptual model of potential mode of BCG action and the expected effect of STING pathway activation to increase chemokine secretion and immune cell recruitment. From: Koti, et al., Bladder Cancer, Vol.5, Iss.3, pp. 225–234, 2019

Systematic review of predictive molecular biomarkers associated with response to PD-1 and PD-L1 inhibitors. The visual illustrates the immune checkpoint blockade in advanced bladder cancer ranking the predictive value. From: Tu, et al., Bladder Cancer, Vol.5, Iss.2, pp. 131–145, 2019

Clinical development of fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of urothelial cancer. The visual illustrates the dimerization of FGFR leading to the phosphorylation of the tyrosine kinase domains. From: Ibrahim, et al., Bladder Cancer, Vol.5, Iss.2, pp. 87–102, 2019

Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities via: tiny.cc/BLC-BCAN_PR

Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the Clinical Trials Corner.